Aclaris Therapeutics – IPO

Reston – October 20, 2015 – Cooley advised Aclaris Therapeutics on its $63.3 million initial public offering. Aclaris is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. The company now trades on The NASDAQ Global Select Market under the symbol "ACRS."

The Cooley corporate and securities team advising Aclaris included partners Brent Siler and Divakar Gupta, special counsel Brian Leaf and associates Mark Ballantyne, Katie Kazem and Katelyn Kimber.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Brian Leaf Partner, Reston
Francis Wheeler Partner, Colorado
MaryBeth Shreiner Associate, Reston
Brent Siler Partner, Washington, DC
Natasha Leskovsek Partner, Washington, DC
Mark Windfeld-Hansen Partner, Palo Alto
Kevin King Partner, Washington, DC
Karen Tsai Associate, Washington, DC
Keith Ranta Special Counsel, Washington, DC
Mark Ballantyne Associate, Reston
Sarah diFrancesca Partner, New York
Phil Mitchell Partner, New York
Div Gupta Partner, New York
Katelyn Kimber Associate, Washington, DC